Posted by admin on Apr 19th, 2022
Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) and Leap Therapeutics (NASDAQ:LPTX – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.
Insider and Institutional Ownership
9.1% of Diffusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.6% of Leap Therapeutics shares are owned by institutional investors. 2.0% of Diffusion Pharmaceuticals shares are owned by insiders. Comparatively, 17.1% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Diffusion Pharmaceuticals and Leap Therapeutics’ net margins, return on equity and return on assets.
Earnings and Valuation
This table compares Diffusion Pharmaceuticals and Leap Therapeutics’ revenue, earnings per share and valuation.
Diffusion Pharmaceuticals has higher earnings, but lower revenue than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than Diffusion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current recommendations and price targets for Diffusion Pharmaceuticals and Leap Therapeutics, as provided by MarketBeat.com.
Leap Therapeutics has a consensus target price of $4.50, suggesting a potential upside of 214.69%. Given Leap Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Leap Therapeutics is more favorable than Diffusion Pharmaceuticals.
Volatility & Risk
Diffusion Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
Leap Therapeutics beats Diffusion Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Diffusion Pharmaceuticals (Get Rating)
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
About Leap Therapeutics (Get Rating)
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Diffusion Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
Heritage Insurance Holdings, Inc. (NYSE:HRTG) Expected to Announce Earnings of $0.13 Per Share
Canopy Growth Co. (NASDAQ:CGC) Expected to Post Earnings of -$0.24 Per Share